• English
  • Korean
  • Chinese
表紙
市場調査レポート - 175035

神経変性疾患:世界の薬剤市場(2011〜2026年)

Neurodegenerative Diseases: World Drug Market 2011-2026

発行 Visiongain
出版日 ページ情報 英文 182 Pages
価格

ご注意:当報告書はDRM(デジタル著作権管理システム)付PDFとなります。 認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。ご不明な点につきましてはお問合せください。

神経変性疾患:世界の薬剤市場(2011〜2026年) Neurodegenerative Diseases: World Drug Market 2011-2026
出版日: 2010年02月11日 ページ情報: 英文 182 Pages
概要

神経変性疾患患者数は2050年までに4倍になると予測されています。神経変性疾患の治療市場には大きなアンメットニーズが残されています。

当レポートでは、多発性硬化症、アルツハイマー病、パーキンソン病などのセグメント別の治療薬動向をまとめ、2009〜2026年の収益動向、研究開発パイプラインなどについて、専門家の見解を交えながら、概略下記の構成でお届けいたします。

第1章 エグゼクティブサマリー

第2章 神経変性疾患:イントロダクション

  • 神経変性疾患とは
  • 多発性硬化症
  • アルツハイマー病
  • パーキンソン病
  • ニューロパシー
  • ハンチントン病
  • 治療法

第3章 世界の神経変性疾患治療薬市場:2009〜2026年

  • 2009年の市場分析
  • 市場予測:2010〜2026年

第4章 多発性硬化症市場

  • 治療法
  • 2009年の市場
  • 市場予測:2010〜2026年
  • Copaxone
  • Avonex
  • Rebif
  • Betaferon
  • Tysabri
  • パイプライン分析

第5章 アルツハイマー病

  • 認可済み薬剤はたった5品目
  • 2009年の市場
  • 市場予測:2010〜2026年
  • Aricept
  • Namenda
  • Exelon
  • パイプライン分析

第6章 パーキンソン病市場

  • 2009年の市場
  • 市場予測:2010〜2026年
  • Sifrol
  • Stalevo & Comtess
  • Requip
  • Azilect
  • 将来の治療法

第7章 ニューロパシー

  • 治療法
  • 抗痙攣剤
  • 2009年の市場
  • 市場予測:2010〜2026年
  • Lyricaの売上予測:2010〜2026年
  • 将来の治療法

第8章 ハンチントン病

  • 2009年の市場
  • 市場予測:2010〜2026年
  • Xenazine
  • パイプライン分析

第9章 筋萎縮性側索硬化症

  • 2009年の市場
  • 市場予測:2010〜2026年
  • Rilutek
  • パイプライン分析

第10章 主要国市場:2010〜2026年

第11章 神経変性疾患市場に影響を及ぼす課題

第12章 専門家の見解

第13章 結論

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

how you can find demand and revenue trends there

Would you like to know how the industry and market for neurodegenerative drug treatments will develop? There will be trends to watch from 2010 onwards, especially areas of revenue growth. You can have our new report now, staying ahead, saving time and aiding your decisions.

The number of patients may quadruple worldwide by 2050. Yet, there remain significant unmet needs in all sectors of the neurodegenerative treatments market.

You can assess those commercial opportunities now, with us providing forecasts for the following drug markets from 2010 to 2026:

  • Multiple sclerosis
  • Alzheimer' s disease
  • Parkinson' s disease
  • Neuropathies
  • Huntington' s disease
  • Amyotrophic lateral sclerosis.

Our new report analyses and discusses strengths, weaknesses and revenue trends of the sector from 2009 to 2026.

All sectors of the market have been expanding, but which will fare best from 2010 onwards? How will those submarkets, and the overall market sector, cope with patent expiries this decade? How will leading national markets perform from 2010 to 2026? What opportunities are there for resolving unmet therapeutic needs?

We show you where the neurodegenerative drug treatment sector is heading. Our report shows you its technological and commercial potential, revealing opportunities, challenges and requirements for success there.

New drugs with improved safety and efficacy can gain significant market shares from 2010 onwards. There remain high revenues to be made in this sector from 2010 to 2026, as we show and explain.

New treatment types - such as oral agents for MS - could re-shape the market from this decade onwards. There will be commercial growth, with important trends to watch.

We show how you could make gains there. Our report makes it quick and practical for you to assess the potential of the industry and market now.

Analysis and expert views to aid your work - so you won' t be left behind

Our new report provides you with revenue forecasts, market share analyses, R&D pipeline developments and expert opinion. That way, you can assess prospects, opportunities and threats in the sector. It is that combination of data that sets us apart.

We include 98 tables and figures and two expert interviews (shown in the accompanying lists). You can stay ahead by ordering our report today, benefiting your analyses and commercial ideas.

World Neurodegenerative Diseases: World Drug Market 2011-2026 shows you revenue trends, opportunities and challenges

Our report gives you the following advantages:

  • You will receive hard data for the neurodegenerative diseases sector - especially our revenue forecasts - helping you to stay ahead
  • You will discover revenue trends for the overall market and its main components from 2009 to 2026 - showing you where commercial potential will lie
  • You will find revenue predictions for leading national markets from 2009 to 2026 (US, Japan, UK, Germany, France, Spain, Italy, China and India)
  • You will learn how the sector can change and adapt from 2010 to 2026
  • You will assess leading organisations in neurodegenerative disease treatment, discovering their activities and prospects
  • You will discover the drivers, restraints, competition and opportunities influencing this sector, including oral agents for MS, outcomes of research and drug targets
  • You will investigate unmet and under-met needs in that sector, with therapeutic requirements and commercial opportunities discussed
  • You will review R&D pipelines, assessing the potential of developments
  • You will view expert opinion from our survey, including interview transcripts
  • You will find out where the sector is heading - technology, competition, revenues and other aspects of the industry and market.

Table of Contents

1. Executive Summary

  • 1.1 Overview of Findings
  • 1.2 Chapter Breakdown
  • 1.3 Research and Analysis Methods

2. Neurodegenerative Diseases: An Introduction

  • 2.1 What Are Neurodegenerative Diseases?
  • 2.2 Multiple Sclerosis (MS)
    • 2.2.1 Treatment Options
  • 2.3 Alzheimer' s Disease
    • 2.3.1 Treatment Options
  • 2.4 Parkinson' s Disease
    • 2.4.1 Treatment Options
  • 2.5 Neuropathies
    • 2.5.1 Neuropathic Pain
    • 2.5.2 Treatment Options
      • 2.5.2.1 Pharmacological Treatments
  • 2.6 Huntington' s Disease
    • 2.6.1 Treatment Options
  • 2.7 Amyotrophic Lateral Sclerosis (ALS)
    • 2.7.1 Treatment Options

3. World Neurodegenerative Diseases Drug Market 2009-2026

  • 3.1 Analysis of the Market in 2009
    • 3.1.1 A Market Dominated by Blockbusters
  • 3.2 Neurodegenerative Diseases: Market Forecast 2010-2026
    • 3.2.1 Market Forecast 2010-2016
    • 3.2.2 Blockbuster Patent Expiries
    • 3.2.3 Symptom Treatment over Disease Modification
    • 3.2.4 Market Forecast 2016-2026
      • 3.2.4.1 Rapid Growth in Smaller Markets

4. Multiple Sclerosis (MS) Market

  • 4.1 Treatment Available for MS
    • 4.1.1 Treatment for Symptoms
    • 4.1.2 Disease-Modifying Medicines
  • 4.2 MS Market in 2009
  • 4.3 MS Market Forecast 2010-2026
    • 4.3.1 Market Forecast 2010-2016
    • 4.3.2 Market Forecast 2016-2026
    • 4.3.3 Oral Treatments
    • 4.3.4 An Approval Pathway for Biosimilars
  • 4.4 Copaxone
    • 4.4.1 Copaxone Sales Forecast 2010-2026
    • 4.4.2 Patent Expiry and Competition
  • 4.5 Avonex
    • 4.5.1 Avonex Sales Forecast 2010-2016
    • 4.5.2 Avonex Long-Term Forecast 2016-2026
  • 4.6 Rebif
    • 4.6.1 Rebif Sales Forecast 2010-2016
    • 4.6.2 Rebif Will Be Challenged Beyond 2016
  • 4.7 Betaferon
    • 4.7.1 Betaferon and Generic Competition
  • 4.8 Tysabri
  • 4.9 MS Pipeline Analysis
    • 4.9.1 Oral Treatments
    • 4.9.2 Monoclonal Antibodies
    • 4.9.3 Vaccines

5. Alzheimer' s Disease Market

  • 5.1 There Are Only Five Drugs Approved for Treating Alzheimer' s
  • 5.2 Analysis of the Market in 2009
  • 5.3 Alzheimer' s Market Forecast 2010-2026
    • 5.3.1 Market Forecast 2010-2016
    • 5.3.2 Market Forecast 2016-2026
  • 5.4 Aricept
    • 5.4.1 Aricept Sales Forecast 2010-2026
  • 5.5 Namenda
    • 5.5.1 Namenda Sales Forecast 2010-2026
  • 5.6 Exelon
    • 5.6.1 Exelon Sales Forecast 2010-2026
  • 5.7 Alzheimer' s R&D Pipeline: Analysis
    • 5.7.1 Gamma Secretase Inhibitors
      • 5.7.1.1 Tau Inhibitors
    • 5.7.2 Immunotherapy
      • 5.7.2.1 Monoclonal Antibodies
      • 5.7.2.2 IVIg
    • 5.7.3 Amyloid-? Detection

6. Parkinson' s Disease Market

  • 6.1 Parkinson' s Market in 2009
  • 6.2 Parkinson' s Market Forecast 2010-2026
  • 6.3 Sifrol
    • 6.3.1 Sifrol Sales Forecast 2010-2026
  • 6.4 Stalevo & Comtess
    • 6.4.1 Stalevo for Early Stage Parkinson' s
    • 6.4.2 Stalevo & Comtess Sales Forecast 2010-2026
  • 6.5 Requip
    • 6.5.1 Requip Sales Forecast 2010-2026
  • 6.6 Azilect
    • 6.6.1 Azilect Delays Disease Progression
    • 6.6.2 Azilect Sales Forecast 2010-2026
  • 6.7 Future Therapy for Parkinson' s
    • 6.7.1 Developments for Levodopa
    • 6.7.2 KW-6002
    • 6.7.3 Safinamide
    • 6.7.4 Gene Therapy Could Soon Be a Treatment Option
      • 6.7.4.1 Ceregene
      • 6.7.4.2 Neurologix
    • 6.7.5 Long-Term Treatment Options

7. Neuropathies Market

  • 7.1 Treatment Options
    • 7.1.1 Anticonvulsants
    • 7.1.2 Analgesics
      • 7.1.2.1 Local Anaesthetics
    • 7.1.3 Antidepressants
    • 7.1.4 Aldose Reductase Inhibitors
      • 7.1.4.1 Kinedak
  • 7.2 Neuropathy Market in 2009
  • 7.3 Neuropathy Market Forecast 2010-2026
    • 7.3.1 Market Forecast 2010-2016
    • 7.3.2 Market Forecast 2016-2026
    • 7.3.3 Neurontin: The Forerunner of Lyrica
    • 7.3.4 Qutenza is a Recently-Approved Neuropathy Treatment
  • 7.4 Lyrica Sales Forecast 2010-2026
    • 7.4.1 Lyrica Patents Expire in 2013 and 2018
  • 7.5 Future Treatment of Neuropathies
    • 7.5.1 AS-3201
    • 7.5.2 KRN5500
    • 7.5.3 Epicept NP-1
    • 7.5.4 Secondary Indication Drugs
    • 7.5.5 J&J and Monoclonal Antibodies

8. Huntington' s Disease Market

  • 8.1 Huntington' s Market in 2009
  • 8.2 Huntington' s Market Forecast 2010-2026
  • 8.3 Xenazine
    • 8.3.1 Xenazine Sales Analysis, 2009
    • 8.3.2 Xenazine Sales Forecast 2010-2026
  • 8.4 R&D Pipeline Analysis
    • 8.4.1 Huntexil
    • 8.4.2 Dimebon
    • 8.4.3 Antioxidant Therapy
    • 8.4.4 RNAi as a Potential Treatment

9. Amyotrophic Lateral Sclerosis (ALS) Market

  • 9.1 ALS Market in 2009
  • 9.2 ALS Market Forecast 2010-2026
    • 9.2.1 ALS Market Forecast: Best Case Scenario
    • 9.2.2 ALS Market Forecast: Worst Case Scenario
  • 9.3 Rilutek
    • 9.3.1 Rilutek Sales Forecast 2010-2026
  • 9.4 R&D Pipeline Analysis
    • 9.4.1 Olesoxime
    • 9.4.2 Mecobalamin
    • 9.4.3 Radicut
    • 9.4.4 Dexpramipexole

10. Leading National Market Forecasts 2010-2026

  • 10.1 US Market: Forecast 2010-2026
  • 10.2 Leading European Markets: Forecasts 2010-2026
  • 10.3 Japanese Market: Forecast 2010-2026
  • 10.4 Leading Emerging Markets: Forecasts 2010-2026
    • 10.4.1 China
    • 10.4.2 India

11. Issues Affecting the Neurodegenerative Diseases Market 2010-2026

  • 11.1 SWOT Analysis of the Neurodegenerative Diseases Market 2010-2026
  • 11.2 Strengths
    • 11.2.1 Neurodegenerative Diseases Are High Profile
    • 11.2.2 Chronic Diseases: Long-Term Repeat Sales
  • 11.3 Weaknesses
    • 11.3.1 Side Effects Associated with Treatment
    • 11.3.2 The High Costs of Treatment
    • 11.3.3 High Product Competition
  • 11.4 Opportunities
    • 11.4.1 Significant Unmet Needs Still Exist in the Market
    • 11.4.2 Aging Populations Will Lead to Increased Disease Prevalence
    • 11.4.3 Orphan Status and Fast Track Reviews for New Drugs
  • 11.5 Threats
    • 11.5.1 Patent Expiries Will Lead to Generic Competition
    • 11.5.2 New Therapies Offer an Alternative to Drug Treatment
      • 11.5.2.1 Neurostimulation
      • 11.5.2.2 Stem Cell Therapy
      • 11.5.2.3 Gene Therapy

12. Expert Opinions

  • 12.1 Interview with Professor Lisa Ellerby
    • 12.1.1 Future Treatment Possibilities
    • 12.1.2 The Market Potential for a Huntington' s Disease Cure
  • 12.2 Interview with Professor Jurgen Gotz
    • 12.2.1 The Obstacles for Developing a Cure for Alzheimer' s Disease
    • 12.2.2 The Time Frame for Developing a Cure for Alzheimer' s Disease
    • 12.2.3 Potential Alzheimer' s Disease Treatments
    • 12.2.4 The Market Potential for a Cure for Alzheimer' s Disease

13. Conclusions

  • 13.1 Rising Prevalence Due to Aging Population to Drive Market Growth
  • 13.2 All Markets Have Significant Unmet Needs
  • 13.3 Pipelines for Some Diseases Are Stronger Than Others
  • 13.4 Conclusions for Individual Market Sectors
    • 13.4.1 Oral Treatments Will Alter the MS Market
    • 13.4.2 Alzheimer' s Symptom Management Therapies Will Remain Competitive
    • 13.4.3 Patent Expiries to Hit the Parkinson' s Market
    • 13.4.4 Indication-Specific Drugs Will Expand the Neuropathies Market
    • 13.4.5 Blockbuster Potential for Novel Huntington' s Drugs
    • 13.4.6 The ALS Market is Difficult to Predict

List of Tables

  • Table 2.1 Prevalence of Neurodegenerative Diseases, 2010
  • Table 2.2 Life Expectancy for Prion Diseases, 2010
  • Table 2.3 Common Causes of Neuropathies, 2010
  • Table 3.1 Neurodegenerative Diseases: Blockbuster Drugs, 2009
  • Table 3.2 World Neurodegenerative Diseases Market Forecast, 2009-2016
  • Table 3.3 Neurodegenerative Diseases Drivers and Restraints, 2010-2026
  • Table 3.4 Blockbuster Patent Expiries, 2009-2015
  • Table 3.5 World Neurodegenerative Diseases Market Forecast, 2016-2026
  • Table 4.1 Leading MS Drug Sales, 2009
  • Table 4.2 MS Drug Market Forecast, 2009-2016
  • Table 4.3 MS Drug Market Forecast, 2016-2026
  • Table 4.4 Selected Pipeline Treatments for MS in Phase II & III, 2010
  • Table 5.1 FDA Approved Alzheimer' s Therapeutics, 2010
  • Table 5.2 Leading Alzheimer' s Drug Sales, 2009
  • Table 5.3 Earliest Expected Approvals for Anti-Alzheimer' s Treatments in Phase III, 2010
  • Table 5.4 Alzheimer' s Drug Market Forecast, 2009-2016
  • Table 5.5 Alzheimer' s Drug Market Forecast, 2016-2026
  • Table 5.6 Selected Pipeline Treatments for Alzheimer' s in Phase II & III, 2010
  • Table 6.1 Leading Parkinson' s Drug Sales, 2009
  • Table 6.2 Patent Expiries Affecting the Parkinson' s Market, 2008-2013
  • Table 6.3 Parkinson' s Drug Market Forecast, 2009-2016
  • Table 6.4 Parkinson' s Drug Market Forecast, 2016-2026
  • Table 6.5 Stalevo & Comtess Sales, 2009
  • Table 6.6 Selected Pipeline Treatments for Parkinson' s in Phase II & III, 2010
  • Table 7.1 Key Therapeutics Indicated for Neuropathies, 2010
  • Table 7.2 Leading Neuropathy Drug Sales, 2009
  • Table 7.3 Neuropathy Drug Market Forecast, 2009-2016
  • Table 7.4 Neuropathy Drug Market Forecast, 2016-2026
  • Table 7.5 The Rising Prevalence of Diabetes, 2010-2030
  • Table 7.6 Selected Pipeline Treatments for Neuropathies in Phase II & III, 2010
  • Table 8.1 Treatment Options for Huntington' s, 2010
  • Table 8.2 Huntington' s Drug Market Forecast, 2009-2016
  • Table 8.3 Huntington' s Drug Market Forecast, 2016-2026
  • Table 8.4 Global Xenazine Sales, 2009
  • Table 8.5 Selected Pipeline Treatments for Huntington' s in Phase II & III, 2010
  • Table 9.1 ALS Drug Market: Best Case Scenario Forecast, 2009-2016
  • Table 9.2 ALS Drug Market: Best Case Scenario Forecast, 2016-2026
  • Table 9.3 ALS Drug Market: Worst Case Scenario Forecast, 2009-2016
  • Table 9.4 ALS Drug Market: Worst Case Scenario Forecast, 2016-2026
  • Table 9.5 Selected Pipeline Treatments for ALS in Phase II & III, 2010
  • Table 10.1 Neurodegenerative Diseases Market: National Forecasts, 2009-2016
  • Table 10.2 Neurodegenerative Diseases Market: National Forecasts, 2016-2026
  • Table 11.1 SWOT Chart for the Neurodegenerative Diseases Market, 2010-2026
  • Table 11.2 Population Proportions (%) Aged Over 65, 2009-2050
  • Table 11.3 Progress of Alternative Therapies for Neurodegenerative Diseases, 2010
  • Table 13.1 World Neurodegenerative Disease Market: Forecast Summary, 2009-2026

List of Figures

  • Figure 2.1 The Five Stages of Parkinson' s Disease
  • Figure 3.1 World Neurodegenerative Diseases: Market Shares by Sector, 2009
  • Figure 3.2 Neurodegenerative Diseases: Blockbuster Drugs, 2009
  • Figure 3.3 World Neurodegenerative Diseases Market Forecast, 2009-2016
  • Figure 3.4 World Neurodegenerative Diseases: Market Shares by Sector, 2016
  • Figure 3.5 World Neurodegenerative Diseases Market Forecast, 2016-2026
  • Figure 3.6 World Neurodegenerative Diseases: Market Shares by Sector, 2026
  • Figure 4.1 Leading MS Drug Sales, 2009
  • Figure 4.2 MS Drug Market Forecast, 2009-2016
  • Figure 4.3 Leading MS Drug Market Shares, 2016
  • Figure 4.4 Leading MS Drug Market Shares, 2026
  • Figure 4.5 MS Drug Market Forecast, 2016-2026
  • Figure 4.6 Copaxone Sales Forecast, 2009-2026
  • Figure 4.7 Avonex Sales Forecast, 2009-2026
  • Figure 4.8 Rebif Sales Forecast, 2009-2026
  • Figure 4.9 Betaferon Sales Forecast, 2009-2026
  • Figure 5.1 Leading Alzheimer' s Drug Sales, 2009
  • Figure 5.2 Alzheimer' s Drug Market Forecast, 2009-2016
  • Figure 5.3 Leading Alzheimer' s Drugs: Market Shares, 2009, 2016 & 2026
  • Figure 5.4 Leading Alzheimer' s Drug Market Forecast, 2016-2026
  • Figure 5.5 Aricept Sales Forecast, 2009-2026
  • Figure 5.6 Namenda Sales Forecast, 2009-2026
  • Figure 5.7 Exelon Sales Forecast, 2009-2026
  • Figure 6.1 Leading Parkinson' s Drug Sales, 2009
  • Figure 6.2 Parkinson' s Drug Market Forecast, 2009-2016
  • Figure 6.3 Parkinson' s Drug Market Forecast, 2016-2026
  • Figure 6.4 Leading Parkinson' s Drugs: Market Shares, 2009, 2016 & 2026
  • Figure 6.5 Sifrol Sales Forecast, 2009-2026
  • Figure 6.6 Stalevo & Comtess Sales, 2009
  • Figure 6.7 Stalevo & Comtess Sales Forecast, 2009-2026
  • Figure 6.8 Requip Sales Forecast, 2009-2026
  • Figure 6.9 Azilect Sales Forecast, 2009-2026
  • Figure 7.1 Leading Neuropathy Drug Sales, 2009
  • Figure 7.2 Neuropathy Drug Market Forecast, 2009-2016
  • Figure 7.3 Neuropathy Drug Market Forecast, 2016-2026
  • Figure 7.4 The Rising Prevalence of Diabetes, 2010-2030
  • Figure 7.5 Lyrica Sales Forecast, 2009-2026
  • Figure 8.1 Huntington' s Drug Market Forecast, 2009-2026
  • Figure 8.2 Global Xenazine Sales, 2009
  • Figure 8.3 Xenazine Sales Forecast, 2009-2026
  • Figure 9.1 ALS Drug Market: Best Case Scenario Forecast, 2009-2026
  • Figure 9.2 ALS Drug Market: Worst Case Scenario Forecast, 2009-2026
  • Figure 9.3 Comparison of ALS Drug Market Scenarios, 2009, 2016 & 2026
  • Figure 9.4 Rilutek Sales Forecast, 2009-2026
  • Figure 10.1 Neurodegenerative Diseases Market: National Shares, 2009
  • Figure 10.2 Neurodegenerative Diseases Market: National Shares, 2016
  • Figure 10.3 Neurodegenerative Diseases Market: National Shares, 2026
  • Figure 10.4 US Market Forecast, 2009-2026
  • Figure 10.5 European Market Forecasts, 2009-2026
  • Figure 10.6 Japanese Market Forecast, 2009-2026
  • Figure 10.7 Chinese and Indian Market Forecasts, 2009-2026
  • Figure 11.1 Proportion of Population Aged Over 65 by Region, 2009-2050

Companies Listed

  • Abbott Laboratories
  • Acadia Pharmaceuticals
  • Actelion
  • Active Biotech
  • Adolor
  • Alliance Pharmaceuticals
  • Alzheimer' s Association
  • Alzheimer' s Disease Cooperative Study
  • Amarin
  • Amneal Pharmaceuticals
  • Astellas Pharma
  • AstraZeneca
  • Avanir Pharmaceuticals
  • Avicena Group
  • Avid Radiopharmaceuticals
  • Baxter Healthcare
  • Bayer
  • Bayhill Therapeutics
  • Biogen Idec
  • Biovail (now Valeant)
  • Boehringer Ingelheim
  • BrainStorm Cell Therapeutics
  • Bristol Myers Squibb
  • Buck Institute for Age Research
  • Cambridge Laboratories
  • Cephalon
  • Ceregene
  • Chelsea Therapeutics
  • Committee for Medicinal Products for Human Use
  • Cytokinetics
  • CytRx
  • Dainippon Sumitomo Pharma
  • Dara Biosciences
  • Depomed
  • Dr. Reddy' s Laboratories
  • Eisai
  • Elan
  • Eli Lilly
  • EMA
  • Endo Laboratories
  • EnVivo Pharmaceuticals
  • EpiCept
  • European Cooperative Network for Research, Diagnosis and Therapy of Parkinson' s Disease
  • EUSA Pharma
  • FDA
  • Forest Laboratories
  • GE Healthcare
  • Gedeon Richter
  • Genentech
  • Genzyme
  • GlaxoSmithKline (GSK)
  • Glenmark Generics
  • Impax Laboratories
  • International Diabetes Federation
  • Johnson and Johnson (J&J)
  • Janssen
  • Knopp Pharmaceuticals
  • Kyowa Hakko Kirin Company
  • LifeHealth
  • Lundbeck
  • Lupin Pharmaceuticals
  • Massachusetts General Hospital
  • Medivation
  • Merck & Co
  • Merck Serono
  • Mitsubishi Tanabe Pharma
  • Momenta Pharmaceuticals
  • Mylan
  • Myriad Genetics
  • Natco
  • National Institute for Neurological Disorders and Stroke (NINDS)
  • National Institute of Aging
  • Neuralstem
  • NeurogesX
  • Neurologix
  • Neuropathy Association
  • NeuroSearch
  • Newron
  • Northwestern University
  • Novartis
  • Nutra Pharma
  • Octapharma
  • Ono Pharmaceuticals
  • Opexa Therapeutics
  • Orchestra Therapeutics
  • Orchid
  • Orion
  • Ovation
  • Pfizer
  • Prestwick Pharmaceuticals
  • Ranbaxy Laboratories (Daiichi-Sanko)
  • Raptor Pharmaceuticals
  • ReceptoPharm
  • Regeneron
  • Roche
  • Roxane
  • Rush University Medical Center
  • Sandoz
  • Sangamo BioSciences
  • sanofi-aventis
  • Santhera Pharmaceuticals
  • Schering Plough
  • Schwarz Pharma (UCB)
  • Shire
  • Solvay Pharmaceuticals (now Abbott Products)
  • Sonexa Therapeutics
  • Sun Pharmaceuticals
  • Synosia Therapeutics
  • Takeda
  • TauRx Pharmaceuticals
  • TCA Cellular Therapy
  • Teikoku Pharma
  • Temmler Pharma
  • Teva
  • Toyama Chemical Co
  • Transition Therapeutics
  • Trophos
  • United Nations (UN)
  • University of Nebraska
  • University of Rochester
  • University of South Florida
  • University of Sydney
  • University of Virginia
  • Upsher-Smith Laboratories
  • Valeant
  • Watson Pharmaceuticals
  • Wockhardt
  • World Health Organisation (WHO)
  • Wyeth (now part of Pfizer)
  • Xenoport
Back to Top